Spruce Biosciences to Participate in September Investor Conferences

Spruce Biosciences (NASDAQ: SPRB), a biopharmaceutical company, announced participation in four investor conferences this September.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

09/07/2021 - 04:05 PM EDT

SAN FRANCISCO--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in four upcoming investor conferences taking place virtually throughout the month of September:

H.C. Wainwright 23rd Annual Global Investment Conference
Date: September 13 – 14, 2021
Format: Company presentation (available September 13 at 7:00 am ET) and 1x1 meetings

Baird 2021 Global Healthcare Conference
Date: September 14 – 15, 2021
Format: Company presentation (September 15 at 1:25 pm ET) and 1x1 meetings

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: September 20 – 22, 2021
Format: Company presentation (September 21 at 11:35 am ET) and 1x1 meetings

SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event
Date: September 22 – 23, 2021
Format: 1x1 meetings

Interested parties can access the webcast for each conference presentation from the Events section of the company’s investor relations website.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. Spruce is also developing tildacerfont for women suffering from a rare form of polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit www.sprucebiosciences.com and follow us on Twitter @Spruce_Bio, LinkedIn, Facebook and YouTube.